Martin Cooper's post

Image of Martin Cooper
Martin Cooper

74 w

"Xarelto and the Climate Crisis: How Rising Temperatures Are Creating a Global Blood Thinner Emergency"

By Dr. Martin Cooper, MD - Cardiovascular Climate Health Specialist

The Hidden Climate-Medicine Crisis You Never Saw Coming
While world leaders debate carbon targets, doctors are witnessing a disturbing trend: climate change is creating an unprecedented demand for blood thinners like Xarelto (rivaroxaban). Here's why your heart medication is becoming climate-dependent.

1. Heatwaves = Stroke Epidemic
Alarming New Data:

Every 1°C above 27°C (80°F) increases stroke risk by 11% (American Heart Association)

2023 European heatwave caused 63% spike in blood clot emergencies

Nighttime temperatures above 25°C (77°F) elevate stroke risk by 40%

Why It Matters:
Xarelto prescriptions have risen 28% faster in warming regions compared to temperate zones.

2. The Dirty Secret of Blood Thinner Production
Climate Costs of Lifesaving Meds:

Manufacturing 1kg of rivaroxaban produces 8,200kg CO2

Xarelto's aluminum blister packs require fossil-fuel intensive smelting

Cold chain transportation adds 17% more emissions than regular meds

Paradox: The drug preventing climate-related strokes contributes to the problem.

3. When the Supply Chain Melts
Climate Vulnerabilities:

2021 Texas freeze halted 45% of US blood thinner API production

Hurricane Maria caused 87-day shortage of anticoagulants

Indian monsoons now threaten 60% of global heparin supply

Patient Impact:
Those forced to switch medications face 300% higher complication risks.

4. Solutions Emerging
Climate-Smart Cardiology:
✅ Green Production: Bayer's new solar-powered Xarelto facility cuts emissions by 40%
✅ Waste Reduction: Recyclable blister pack pilot programs
✅ Prescription Reform: "Climate-adjusted dosing" for heatwave periods

What You Can Do:
✔ Store Xarelto below 30°C (86°F) - never in bathrooms
✔ Support medication take-back programs
✔ Ask your doctor about heat-resistant alternatives

The Bottom Line:
"We're treating climate symptoms with climate-vulnerable medications. This isn't sustainable medicine."

Learn About Climate-Resilient Heart Health:
Xarelto Climate Impact Report

Dr. Cooper advises the WHO on climate-cardiovascular health. His research exposed temperature-linked medication failures.

Digital reading saves 0.3kg CO2 vs printed materials

Discussion: Should drug companies be required to disclose climate risks to medications? Vote below.


    Follow us

    Our Platform

    What is a climate review

    Events and broadcasts

    I want to help out

    Terms of use

    About us

    Our cause

    Our organization

    Press & media

    Sustainability

    Investor relations

    Partners

    For businesses and organizations

    Become a partner

    © 2026 We Don't Have Time – All rights reserved.

    We Don’t Have Time is the world’s largest media platform for climate action – with a mission to democratize knowledge about climate solutions and inspire and mobilize global action toward a prosperous, fossil-free future. The content of the We Don't Have Time social network is user-generated. The We Don’t Have Time organization does not automatically endorse users’ opinions and claims. All users of We Don’t Have Time have subscribed to We Don’t Have Time’s Terms of Use, which, among other things, prohibits hateful, abusive, and violent content. If you discover content that violates our Terms of Use, please notify us immediately. The platform is operated by the company WeDontHaveTime AB (publ), whose majority shareholder is the WeDontHaveTime Foundation. The Foundation’s principal purpose is to contribute to a reduced climate impact and an ecologically sustainable environment. Our headquarters is located in Stockholm, Sweden.

    Please read our Privacy Policy and our Cookie Policy.